Connect Biopharma Holdings Limited (CNTB)
NASDAQ: CNTB · Real-Time Price · USD
2.020
-0.070 (-3.35%)
At close: Jul 31, 2026, 4:00 PM EDT
2.022
+0.002 (0.10%)
After-hours: Jul 31, 2026, 7:34 PM EDT
CNTB Revenue
Connect Biopharma Holdings had revenue of $169.00K in the quarter ending March 31, 2026. This brings the company's revenue in the last twelve months to $233.00K, down -99.10% year-over-year. In the year 2025, Connect Biopharma Holdings had annual revenue of $64.00K, down -99.75%.
Revenue (ttm)
$233.00K
Revenue Growth
-99.10%
P/S Ratio
545.87
Revenue / Employee
$3,641
Employees
64
Market Cap
127.19M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 64.00K | -25.97M | -99.75% |
| Dec 31, 2024 | 26.03M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Jan 1, 2022 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionCNTB News
- 18 days ago - Connect Biopharma Holdings Slides: Corporate presentation - Filings
- 24 days ago - Connect Biopharma initiated with an Outperform at Oppenheimer - TheFly
- 5 weeks ago - Connect Biopharma initiated with an Overweight at Piper Sandler - TheFly
- 6 weeks ago - Connect Biopharma Announces Completion of Enrollment of Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma - GlobeNewsWire
- 2 months ago - Connect Biopharma initiated with a Buy at Canaccord - TheFly
- 2 months ago - Connect Biopharma initiated with an Overweight at Cantor Fitzgerald - TheFly
- 2 months ago - Connect Biopharma initiated with an Overweight at Cantor Fitzgerald - TheFly
- 2 months ago - Connect Biopharma Holdings Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference - Transcripts